Literature DB >> 32895703

Reliability and Validity of the Boston Bedside Quantitative Sensory Testing Battery for Neuropathic Pain.

Alexandra E Koulouris1, Robert R Edwards1, Kathleen Dorado1, Kristin L Schreiber1, Asimina Lazaridou1, Sharika Rajan2, Jeffrey White2, Jenniffer Garcia2, Christopher Gibbons2, Roy Freeman2.   

Abstract

OBJECTIVE: Recent studies suggest that sensory phenotyping may provide critical information for the diagnosis and management of patients with chronic neuropathic pain (NP). However, many formal quantitative sensory testing (QST) paradigms require expensive equipment, a dedicated location, and substantial time commitments on the part of patient and examiner, highlighting the need for a convenient and portable "bedside" QST battery. We developed and tested a bedside QST battery in a sample of patients with chronic NP.
METHODS: Participants (N = 51) attended two in-person visits over approximately two weeks, during which they underwent QST using both laboratory-based equipment and simple, easily accessible bedside tools. Participants also completed questionnaires about their daily pain and NP symptoms.
RESULTS: Test-retest reliability estimates were highly statistically significant and did not differ between bedside (mean r = 0.60) and laboratory-based (mean r = 0.72) QST. Bedside QST variables and corresponding laboratory-based QST variables were highly correlated, suggesting adequate criterion validity for the bedside tests.
CONCLUSIONS: Results from the present study may have important implications for the sensory phenotyping and subsequent management of patients with chronic NP. Implementation of a protocol that uses inexpensive, portable, and convenient tools may allow for the application of QST in variety of clinical settings and advance NP research.
© The Author(s) 2020. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Neuropathic; Pain; Quantitative Sensory Testing

Year:  2020        PMID: 32895703      PMCID: PMC7593797          DOI: 10.1093/pm/pnaa192

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  48 in total

Review 1.  Epidemiology of neuropathic pain and its impact on quality of life.

Authors:  Blair H Smith; Nicola Torrance
Journal:  Curr Pain Headache Rep       Date:  2012-06

Review 2.  The painDETECT project - far more than a screening tool on neuropathic pain.

Authors:  Rainer Freynhagen; Thomas R Tölle; Ulrich Gockel; Ralf Baron
Journal:  Curr Med Res Opin       Date:  2016-03-11       Impact factor: 2.580

3.  Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome?

Authors:  Nadine Attal; Didier Bouhassira; Ralf Baron; Jonathan Dostrovsky; Robert H Dworkin; Nanna Finnerup; Geoffrey Gourlay; Maija Haanpaa; Srinivasa Raja; Andrew S C Rice; David Simpson; Rolf-Detlef Treede
Journal:  Eur J Pain       Date:  2011-03-31       Impact factor: 3.931

4.  Painful and painless peripheral sensory neuropathies due to HIV infection: a comparison using quantitative sensory evaluation.

Authors:  D Bouhassira; N Attal; J C Willer; L Brasseur
Journal:  Pain       Date:  1999-03       Impact factor: 6.961

5.  The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study.

Authors:  Dyveke T Demant; Karen Lund; Jan Vollert; Christoph Maier; Märtha Segerdahl; Nanna B Finnerup; Troels S Jensen; Søren H Sindrup
Journal:  Pain       Date:  2014-08-17       Impact factor: 6.961

6.  The evidence for pharmacological treatment of neuropathic pain.

Authors:  Nanna Brix Finnerup; Søren Hein Sindrup; Troels Staehelin Jensen
Journal:  Pain       Date:  2010-09       Impact factor: 6.961

7.  Allodynia in patients with post-stroke central pain (CPSP) studied by statistical quantitative sensory testing within individuals.

Authors:  D J Greenspan; S Ohara; E Sarlani; A F Lenz
Journal:  Pain       Date:  2004-06       Impact factor: 6.961

8.  Development and validation of the Neuropathic Pain Symptom Inventory.

Authors:  Didier Bouhassira; Nadine Attal; Jacques Fermanian; Haiel Alchaar; Michèle Gautron; Etienne Masquelier; Sylvie Rostaing; Michel Lanteri-Minet; Elisabeth Collin; Jacques Grisart; François Boureau
Journal:  Pain       Date:  2004-04       Impact factor: 6.961

9.  Pain sensitivity profiles in patients with advanced knee osteoarthritis.

Authors:  Laura A Frey-Law; Nicole L Bohr; Kathleen A Sluka; Keela Herr; Charles R Clark; Nicolas O Noiseux; John J Callaghan; M Bridget Zimmerman; Barbara A Rakel
Journal:  Pain       Date:  2016-09       Impact factor: 7.926

10.  Investigating the validity of the DN4 in a consecutive population of patients with chronic pain.

Authors:  Hans Timmerman; Monique A H Steegers; Frank J P M Huygen; Jelle J Goeman; Nick T van Dasselaar; Marcel J Schenkels; Oliver H G Wilder-Smith; André P Wolff; Kris C P Vissers
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

View more
  7 in total

1.  Quantitative and Fiber-Selective Evaluation for Central Poststroke Pain.

Authors:  Jian-Min Chen; Qing-Fa Chen; Zhi-Yong Wang; Guo-Xin Ni
Journal:  Neural Plast       Date:  2022-06-06       Impact factor: 3.144

2.  Randomized, double-blind, placebo-controlled trial of ISC 17536, an oral inhibitor of transient receptor potential ankyrin 1, in patients with painful diabetic peripheral neuropathy: impact of preserved small nerve fiber function.

Authors:  Sunil M Jain; Ramanathan Balamurugan; Monika Tandon; Neelufar Mozaffarian; Girish Gudi; Yacine Salhi; Robert Holland; Roy Freeman; Ralf Baron
Journal:  Pain       Date:  2021-09-02       Impact factor: 7.926

Review 3.  Understanding the Psychological, Physiological, and Genetic Factors Affecting Precision Pain Medicine: A Narrative Review.

Authors:  Andrea Chadwick; Andrew Frazier; Talal W Khan; Erin Young
Journal:  J Pain Res       Date:  2021-10-08       Impact factor: 3.133

4.  Modified Sensory Testing in Non-verbal Patients Receiving Novel Intrathecal Therapies for Neurological Disorders.

Authors:  Laura Cornelissen; Carolina Donado; Timothy W Yu; Charles B Berde
Journal:  Front Neurol       Date:  2022-02-10       Impact factor: 4.003

5.  Detection of altered pain facilitatory and inhibitory mechanisms in patients with knee osteoarthritis by using a simple bedside tool kit (QuantiPain).

Authors:  Masashi Izumi; Yoshihiro Hayashi; Ryota Saito; Shota Oda; Kristian Kjær Petersen; Lars Arendt-Nielsen; Masahiko Ikeuchi
Journal:  Pain Rep       Date:  2022-04-01

6.  Changes in Pain Sensitivity in Treatment for Breast Cancer: A 12-Month Follow-Up Case Series.

Authors:  Laura Lorenzo-Gallego; Beatriz Arranz-Martín; Helena Romay-Barrero; Virginia Prieto-Gómez; Enrique Lluch; María Torres-Lacomba
Journal:  Int J Environ Res Public Health       Date:  2022-03-29       Impact factor: 3.390

Review 7.  Idiopathic distal sensory polyneuropathy: ACTTION diagnostic criteria.

Authors:  Roy Freeman; Jennifer S Gewandter; Catharina G Faber; Christopher Gibbons; Simon Haroutounian; Giuseppe Lauria; Todd Levine; Rayaz A Malik; J Robinson Singleton; A Gordon Smith; Josh Bell; Robert H Dworkin; Eva Feldman; David N Herrmann; Ahmet Hoke; Noah Kolb; Heikki Mansikka; Anne Louise Oaklander; Amanda Peltier; Michael Polydefkis; Elissa Ritt; James W Russell; Stephen Sainati; Deborah Steiner; Roi Treister; Nurcan Üçeyler
Journal:  Neurology       Date:  2020-10-14       Impact factor: 9.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.